- CancerNetwork.com
- CureToday.com
- OncLive.com
- TargetedOnc.com
- Privacy
- Terms & Conditions
- Do Not Sell My Information
© 2022 MJH Life Sciences™ and Oncology Nursing News. All rights reserved.
Lindsay Fischer
Lindsay Fischer is the Associate Editor at ONN. She joined MJH life sciences in 2021 after graduating from Rutgers University with majors in both English and Spanish and a minor in creative writing. When she is not writing, or researching the latest oncology nursing news, Lindsay is an amateur backpacker and rollerblader. Email Lindsay at lfischer@mjhlifesciences.com
Articles
Oral SERD Elacestrant Shows Significant PFS Improvement in ER+/HER2– Advanced Breast Cancer
October 06, 2022
Article
Elacestrant, an oral selective estrogen receptor degrader, may hold the potential to replace intramuscular fulvestrant injections for patients with endocrine receptor–positive, HER2-negative breast cancer.
FDA Approves Futibatinib for Pretreated, Advanced or Metastatic Intrahepatic Cholangiocarcinoma with FGFR2 Rearrangements
October 05, 2022
Article
Futibatinib is now approved to treat patients with previously treated unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma. The agent comes with warnings for ocular toxicities, and hyperphosphatemia and soft tissue mineralization.
Barber Discusses the Integration of Durvalumab/Chemotherapy Combination as New Standard of Care in Biliary Tract Cancers
October 04, 2022
Article
Kristin Barber, APRN, AOCNP, FNP-BC, unpacks the FDA approval of durvalumab in combination with cisplatin and gemcitabine for patients with biliary tract cancers.
Milagros Elia Underscores How Oncology Nursing and Climate Health Are Intertwined
October 01, 2022
Podcast
In this episode of The Vitals, Milagros Elia, MA, APRN, ANP-BC, highlights how oncology nurses play a role in ongoing conversations regarding the intersection of climate change and public health.
Lenalidomide/Rituximab Represents an Acceptable Chemo-Free Regimen for Advanced Follicular Lymphoma
September 30, 2022
Article
Six-year follow-up data showed an overall survival rate of 89% among patients with follicular lymphoma who received either lenalidomide plus rituximab or immunochemotherapy.
5-Year Follow-Up Suggests Luspatercept Safely Reduces Anemia in Patients With Lower-Risk Myelodysplastic Syndromes
September 30, 2022
Article
A significant portion of patients with lower-risk myelodysplastic syndromes achieved red-blood transfusion independence with luspatercept with no new safety signals.
Rise of Oral Cancer Drugs Signal Deeper Financial Toxicity Issues for Patients
September 28, 2022
Article
Mary Anderson, BSN, RN, OCN; and Christina Bach, MBE, MSW, LCSW, OSW-C, FAOSW, discuss approaches to help patients navigate financial toxicity and insurance coverage in the age of oral anticancer drugs.
Climate Change and Evolving Threats to Public Health: The Oncology Nurse’s Role
September 27, 2022
Article
Milagros Elia, MA, APRN, ANP-BC, discusses ways that nurses can advocate for their patients and help them manage health-related symptoms in the context of changing local environments.
Selpercatinib Is Approved for 2 RET Fusion–Positive Solid Tumors, Non–Small Cell Lung Cancer
September 26, 2022
Article
Selpercatinib was approved by the FDA for RET fusion–positive non–small cell lung cancer and locally advanced or metastatic RET fusion–positive solid tumors.
Intense-Modulated Radiation Therapy Reduces Chronic Diarrhea and Urinary Toxicity in Women With Cervical or Endometrial Cancer
September 26, 2022
Article
Intense-modulated therapy was associated with less patient-reported toxicities than conventional radiotherapy and demonstrated a comparable efficacy profile.